These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17508279)

  • 1. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
    Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
    Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
    Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
    Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
    Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
    Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
    Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT
    Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically.
    Yuan X; Zhang Q; Li Z; Zhang X; Bao S; Fan D; Ru Y; Dong S; Zhang Y; Zhang Y; Ye Z; Xiong D
    Cancer Lett; 2016 Oct; 381(1):85-95. PubMed ID: 27450327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.
    Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Curiel DT
    J Ovarian Res; 2016 Jun; 9(1):38. PubMed ID: 27349517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
    Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
    Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
    González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
    J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.
    Zhu ZB; Rivera AA; Makhija SK; Lu B; Wang M; Izumi M; Cerfolio RJ; Stoff-Khalili MA; Zhou F; Takayama K; Siegal GP; Curiel DT
    Lung Cancer; 2007 Feb; 55(2):145-56. PubMed ID: 17113184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors.
    Hernandez-Alcoceba R; Pihalja M; Wicha MS; Clarke MF
    Hum Gene Ther; 2000 Sep; 11(14):2009-24. PubMed ID: 11020800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
    Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.
    van Beusechem VW; Mastenbroek DC; van den Doel PB; Lamfers ML; Grill J; Würdinger T; Haisma HJ; Pinedo HM; Gerritsen WR
    Gene Ther; 2003 Nov; 10(23):1982-91. PubMed ID: 14528322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
    Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
    Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.